PLRZ Share Price Performance
Recent PLRZ News & Updates
No updates
Polyrizon Ltd. Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.14
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Polyrizon Ltd. Competitors
About PLRZ
- Founded
- 2005
- Employees
- 4
- CEO
- WebsiteView website
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.
Israeli Market Performance
- 7 Days: -1.5%
- 3 Months: 21.3%
- 1 Year: 66.8%
- Year to Date: 28.8%
Over the last 7 days, the market has dropped 1.5%, driven by a loss of 1.9% in the Financials sector. As for the longer term, the market has actually risen by 67% in the last year. As for the next few years, earnings are expected to grow by 16% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading